Hepatitis C - Human Genome Sciences: challenging the pegylated interferons

Human Genome Sciences: challenging the pegylated interferons
Pharmaceutical Business Review - Mar 15 8:51 PM
Interim results of a phase II trial of Human Genome Sciences Albuferon in combination with ribavirin showed a significant antiviral effect in non-responders at 48 weeks of treatment. Although its favorable once-monthly dosing puts Albuferon in a strong position to potentially replace pegylated interferon, the drugs success might be delayed by the approval of specific HCV inhibitors.Save to My Web

Peregrine Pharmaceuticals Files Shelf Registration Statement
[Press Release] PR Newswire via Yahoo! Finance - Mar 31 9:13 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission which, when declared effective by the SEC, will allow Peregrine from time to time to offer and sell up to fifteen Save to My Web

Achillion Pharmaceuticals files for IPO
BizJournals - Apr 03 8:23 AM
Achillion Pharmaceuticals Inc. of New Haven, Conn., has filed a registration statement on Form S-1 with the Securities and Exchange Commission for the proposed initial public offering of shares of its common stock. All shares of the common stock in the offering would be sold by Achillion.Save to My Web

XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2005
FinanzNachrichten - Mar 20 11:08 AM
NEW YORK, March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals, ( Nachrichten ) Ltd. , a biotechnology company focused on the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C, today announced its financial results for year ended December 31, 2005.Save to My Web

Human Genome Sciences: Challenging the Pegylated Interferons
RedNova - Mar 15 11:32 AM
Interim results of a phase II trial of Human Genome Sciences' Albuferon in combination with ribavirin showed a significant antiviral effect in non-responders at 48 weeks of treatment.Save to My Web

Coley Pharmaceutical Group Announces Top-line Data from a Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Mar 21 5:30 AM
Coley Pharmaceutical Group, Inc. today announced positive top-line interim data from the company's twelve-week, randomized, controlled clinical study of Actilon in combinations with pegylated interferon and/or ribavirin for the treatment of chronic Hepatitis C virus in the relapsed subset of treatment experienced patients.Save to My Web